ClinicalTrials.gg
CompletedNCT06609174Updated Oct 13, 2026Results posted

AI-SCREENDCM Decentralized Clinical Trial - Pilot Study

An interventional study of KardiaRx ECG Screening and AI interpretation of ECG in Cardiomyopathy, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Screening

How we know

Updated Oct 13, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
119
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Cardiomyopathies by Mayo Clinic — 4 open to participants now, 4 under way, none of them phase 3. Cardiomyopathies · Mayo Clinic.

Started
2024
the only one that year
No phase
2 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Cardiomyopathies by Mayo Clinic, this one is the only one that started in 2024, is one of 2 with no phase, and was the 10th registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

4 of the 11 studies in Cardiomyopathies by Mayo Clinic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cardiomyopathies by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.

03

Conditions studied

  • Cardiomyopathy

Browse trials for

Keywords

  • Artificial Intelligence
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Proband)

  • Male or female age ≥ 18 years
  • Confirmed diagnosis of DCM determined at the discretion of the treating physician and defined as ≤ 45% at any time during the clinical course of the patient
  • Must have at least one living ≥ 18 years FDR
  • Able to provide

Inclusion Criteria (FDR)

  • Male or female age ≥ 18 years who are first-degree relatives of patients with DCM
  • Proband has provided informed consent
  • FDR able to provide informed consent
  • Access to a smartphone or digital tablet with cellular data or Wi-Fi access

Exclusion Criteria (Proband)

  • DCM attributed to any other secondary form of cardiomyopathy per the investigator's determination
  • Proband has previously informed FDR to undergo cardiac screening
  • Ischemic cause of reduced LVEF

    • evidence of myocardial infarction, inducible ischemia or chest pain on stress testing in absence of coronary angiogram to rule out ischemic disease
    • history of acute coronary syndromes (STEMI, NSTEMI or unstable angina) revascularization or ≥75% stenosis of either left main or LAD or ≥75% stenosis of 2 major epicardial vessels on angiogram
  • Moderate or greater primary valvular abnormality not due to underlying cardiomyopathy
  • Congenital structural heart disease
  • Severe and untreated or untreatable hypertension
  • Cardiomyopathy due to acute or reversible conditions; examples include tachyarrhythmias, thyroid disorders, iron overload
  • Any secondary cause of reduced LVEF such as peripartum cardiomyopathy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug
  • (CPC Participants only) Home address outside of traveling range

Exclusion Criteria (FDR)

  • Previously informed about cardiac screening or has completed cardiac screening by TTE
  • Previously diagnosed with reduced LVEF
  • (CPC Participants only) Home address outside of traveling range
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    First degree relatives

    Subjects who are first-degree relatives of patients with DCM

    Diagnostic Test: KardiaRx ECG Screening and AI interpretation of ECG

  • Experimental
    DCM (Dilated Cardiomyopathy) Patients

    Subjects who are diagnosed with DCM (dilated cardiomyopathy).

    Diagnostic Test: KardiaRx ECG Screening and AI interpretation of ECG

Interventions

  • Diagnostic testKardiaRx ECG Screening and AI interpretation of ECG

    The Kardia 6-lead device is an ambulatory, wireless device that connects to a smartphone. The KardiaRx App processes the signal acquired from the Kardia device into a real-time ECG. ECG will be interpreted by an AI algorithm

06

What researchers measure

Primary outcomes

  1. Number of First-Degree Relatives to Complete the AI-ECG

    Measured by the number of subjects who had a complete transmission from the Kardia 6-lead device to the AI-ECG algorithm.

    Time frame: Baseline

  2. Number of First-Degree Relatives to Complete Cardiac Screening

    The number of subjects who completed cardiac screening (i.e. had a scheduled or Completed TTE or had a scheduled or completed clinician visit for the purposes of generating a cardiac evaluation).

    Time frame: Baseline

Secondary outcomes

  1. Number of Subjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤45%

    Number of participants with a positive AI-ECG result, defined as an AI-predicted left ventricular ejection fraction (LVEF) of 45% or less. ECGs were obtained using the AliveCor Kardia 6L device and analyzed using FDA-cleared AI software designed to detect reduced LVEF (≤45%).

    Time frame: Baseline

07

Results

Posted Oct 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneFirst Degree RelativesDCM (Dilated Cardiomyopathy) Patients
Started6647
Completed5847
Not completed80
Withdrew: Did not complete ecg recording80

Outcome measures

PrimaryNumber of First-Degree Relatives to Complete the AI-ECG

Measured by the number of subjects who had a complete transmission from the Kardia 6-lead device to the AI-ECG algorithm.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of First-Degree Relatives to Complete the AI-ECG
ParticipantsFirst Degree RelativesDCM (Dilated Cardiomyopathy) Patients
Number of First-Degree Relatives to Complete the AI-ECG58—
PrimaryNumber of First-Degree Relatives to Complete Cardiac Screening

The number of subjects who completed cardiac screening (i.e. had a scheduled or Completed TTE or had a scheduled or completed clinician visit for the purposes of generating a cardiac evaluation).

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of First-Degree Relatives to Complete Cardiac Screening
ParticipantsFirst Degree RelativesDCM (Dilated Cardiomyopathy) Patients
Number of First-Degree Relatives to Complete Cardiac Screening14—
SecondaryNumber of Subjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤45%

Number of participants with a positive AI-ECG result, defined as an AI-predicted left ventricular ejection fraction (LVEF) of 45% or less. ECGs were obtained using the AliveCor Kardia 6L device and analyzed using FDA-cleared AI software designed to detect reduced LVEF (≤45%).

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Subjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤45%
ParticipantsFirst Degree RelativesDCM (Dilated Cardiomyopathy) Patients
Number of Subjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤45%15—

Adverse events

Collected over Adverse events were collected from the time of informed consent through study completion, approximately 2 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
First Degree Relatives0/66 (0%)0/66 (0%)0/66 (0%)
DCM (Dilated Cardiomyopathy) Patients0/47 (0%)0/47 (0%)0/47 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)First Degree RelativesDCM (Dilated Cardiomyopathy) PatientsTotal
Median45 (36 to 61)65 (57 to 71)56 (40 to 68)
Sex: Female, Male
Sex: Female, Male(Participants)First Degree RelativesDCM (Dilated Cardiomyopathy) PatientsTotal
Female332154
Male332659
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)First Degree RelativesDCM (Dilated Cardiomyopathy) PatientsTotal
Hispanic or Latino314
Not Hispanic or Latino6244106
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)First Degree RelativesDCM (Dilated Cardiomyopathy) PatientsTotal
American Indian or Alaska Native112
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American213
White6042102
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)First Degree RelativesDCM (Dilated Cardiomyopathy) PatientsTotal
United States6647113
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Sep 2025, 11 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 41 non-industry interventional studies with no phase under Cardiomyopathies, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 53. This study's 11 months is below that.

Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 24, 2024
StartActual
Oct 18, 2024
Primary completionActual
Sep 26, 2025
CompletionActual
Sep 26, 2025
Results first posted
Oct 13, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 13, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedAny secondary cause of reduced LVEF such as pregnancyperipartum cardiomyopathy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug
Oct 13, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedNumber of First-Degree Relatives to completeComplete the AI-ECGTime frame: Baseline
  • EditedNumber of First-Degree relativesRelatives to complete cardiac screeningComplete Cardiac ScreeningTime frame: Baseline
Oct 13, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of subjects withSubjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤ 45%Time frame: Baseline
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Results posted
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedAny secondary cause of reduced LVEF such as pregnancyperipartum cardiomyopathy, myocarditis, amyloidosis, sarcoidosis, exposure to toxins including alcohol, substance abuse or chemotherapeutic drug
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedNumber of First-Degree Relatives to completeComplete the AI-ECGTime frame: Baseline
    • EditedNumber of First-Degree relativesRelatives to complete cardiac screeningComplete Cardiac ScreeningTime frame: Baseline
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of subjects withSubjects With an AI ECG-Predicted Left Ventricular Ejection Fraction ≤ 45%Time frame: Baseline
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06609174
Lead sponsor
Mayo Clinic
Responsible party
Naveen L. Pereira (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 24, 2024
Start date
Oct 18, 2024
Primary completion
Sep 26, 2025
Completion
Sep 26, 2025
Results posted
Oct 13, 2026
Last update
Oct 13, 2026

Study contacts

Naveen Pereira, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion